Latest research on Velcade

Bortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.

Latest findings

She was treated with Revlimid, Velcade, and Dexamethasone beginning in February 2013. [source, 2016]
He was also treated with Velcade, Dexamethasone, and Revlimid before undergoing autologous stem cell transplant in February 2014. [source, 2016]
In our patient, her donor-derived multiple myeloma was treated with Velcade, Revlimid, and Dexamethasone followed by autologous stem cell transplantation. [source, 2016]
Sources of major biochemical reagents are as follows: PS-341 (LC Laboratories, USA); epoxomicin and Ub-VS (Boston Biochem, USA); ATP (Calbiochem, USA); ATPγS (Jena Bioscience, Germany); ubiquitin (Sigma); MG132 (Bachem); suc-LLVY-AMC (Bachem); Z-LLE-AMC (Enzo Life Sciences); Boc-LRR-AMC (Enzo Life Sciences). [source, 2016]
A microarray analysis for miR gene expression was performed in hepatocellular carcinoma HepG2 cells after treatment with a proteasome inhibitor PS-341 (50 nM) for 24 h. [source, 2016]
To confirm the results of microarray analysis, the expressions of miR-30b-5p and miR-30c-5p were further examined in a proteasome inhibitor PS-341 dose-dependent manner, by real-time PCR analysis (qPCR) in both HepG2 and MDA-MB-453 cells (Fig. 1B). [source, 2016]
The expression of these miRs was all upregulated dose-dependently in cells treated with PS-341, compared with the control cells. [source, 2016]
Taken together, these data indicate that the expressions of miR-30b-5p and miR-30c-5p can be upregulated by PS-341 treatment. [source, 2016]
The CCK8 assay showed that cell viability was increased by ectopic expression of miR-30b-5p or miR-30c-5p in both HepG2 and MDA-MB-453 cells; and conversely, the cell viability was decreased by inhibition of miR-30b-5p or miR-30c-5p with specific inhibitor both under the basal cell culture condition and after PS-341 treatment (50 nM, 24 h) (Fig. 2A). [source, 2016]
After treatment with PS-341, the percentage of apoptotic and necrotic cells (FITC Annxin V+/PI+) was significantly lower in HepG2 and MDA-MB-453 cells overexpressing either of the two PS341-induced miRs, and conversely, was higher in cells with either one of these miRs being inhibited with specific inhibitor, compared with negative control cells (Fig. 2B). [source, 2016]